Synergy Ablation System
AtriCure, Inc. · Decision date May 6, 2026
What did the FDA approve?
FDA records P100046/S020 as a supplement to PMA P100046, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated May 6, 2026.
FDA approval order statement
approval for labeling changes intended to enhance the safe use of the device
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- May 6, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P100046/S020
- Regulatory pathway
- PMA supplement
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- Decision code
- APPR
- Decision date
- May 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100046. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100046 · Original PMA
ATRICURE SYNERGY ABLATION SYSTEM
P100046/S020 received
Application receipt date recorded by FDA.
P100046/S020 · FDA decision
Special (Immediate Track)
P100046/S021 · Related supplement
Synergy Ablation System
Timeline entries are records held by MedtechLedger for P100046. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100046
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| AtriCure, Inc. | PMA approval | Dec 14, 2011 | FDA | |
Synergy Ablation SystemP100046/S021 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code OCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EPi- Sense ST Coagulation SystemP200002/S015 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| AtriCure, Inc. | PMA supplement | May 6, 2026 | FDA | |
EPi-Sense ST Coagulation SystemP200002/S013 | AtriCure, Inc. | PMA supplement | Nov 14, 2025 | FDA |
EPi-Sense Guided Coagulation SystemP200002/S012 | AtriCure, Inc. | PMA supplement | Oct 7, 2025 | FDA |
| AtriCure, Inc. | PMA approval | Apr 28, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AtriCure, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7555 Innovation Way, Mason, OH, 45040
Sources and methodology
- Original FDA record: P100046/S020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




